TriSalus Publishes Data on Enhanced Tumor Therapy Using PEDD™ and TriNav®

TriSalus Life Sciences®, Inc. (Nasdaq: TLSI), an oncology company focusing on the integration of novel delivery technologies with standard treatments and immunotherapy for liver and pancreatic tumors, has announced a significant advancement in cancer treatment. Their new research, titled "Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model," has been published in the Journal of Vascular and Interventional Radiology.

The study highlights the efficacy of the Pressure-Enabled Drug Delivery (PEDD) method using the TriNav Infusion System. This system significantly improves the delivery and penetration of glass microspheres (GM) into liver tumors and surrounding tissue, compared to traditional microcatheter methods. The research involved a transgenic pig model with induced liver tumors and demonstrated that GM penetration was deeper and more efficient when PEDD was utilized.

Bryan F. Cox, Ph.D., Chief of Research for TriSalus, emphasized that the PEDD approach addresses a critical challenge in oncology by ensuring selective and increased therapeutic delivery to tumors. The study observed that using both proximal and distal placements of the PEDD device resulted in significantly improved delivery of GM to tumors. This improvement was quantified on a millimeter scale, suggesting that the method could target multiple tumors simultaneously, especially in patients with a high disease burden.

Mary Szela, CEO and President of TriSalus, underscored the growing body of evidence supporting the PEDD method's broad applicability. Efficient delivery of therapeutics into tumor cells without damaging surrounding healthy tissue remains a challenge in cancer care. The study confirms that the PEDD method enhances GM uptake regardless of whether the delivery was lobar or selective. This advancement could revolutionize the controlled and targeted delivery of glass microspheres and other drugs into tumors.

The study also suggests that the PEDD method could offer a new approach to treating liver cancer, particularly by improving the safety and efficacy of treatments such as selective Y90 used for more advanced diffuse disease. By altering hemodynamics and the tumor microenvironment, PEDD results in higher concentrations of microspheres in tumors compared to adjacent liver tissue. This improved delivery method holds potential for increasing treatment efficacy while maintaining patient safety.

Dr. Riad Salem, Chief of Interventional Radiology, and Professor of Radiology, Surgery, and Medicine in Chicago, commented on the study's potential impact on liver cancer therapy. The results indicate that PEDD could be a significant advancement in managing liver cancer by achieving higher concentrations of therapeutics in tumors with a safety profile comparable to established treatments.

The research involved infusing fluorescently labeled GM into liver tumors in transgenic pigs using the PEDD method with the TriNav device. This approach was compared to the conventional microcatheter delivery method in both lobar and selective infusions. Utilizing near-infrared imaging, the study detected significant increases in GM signal intensity in tumors. Specifically, PEDD delivery resulted in a 117% increase in tumor penetration for lobar infusions and a 39% increase for selective infusions compared to conventional methods. The study concluded that lobar PEDD delivery of GM to tumors was statistically equivalent to conventional selective delivery.

TriSalus Life Sciences® continues to focus on developing innovative technologies to improve cancer treatment outcomes. The company's platform includes FDA-cleared devices that utilize the proprietary PEDD approach for delivering therapeutics to liver and pancreatic tumors. Their ongoing research and partnerships with leading cancer centers aim to advance patient care by overcoming existing therapeutic delivery challenges.